EMT signaling: potential contribution of CRISPR/Cas gene editing.


Journal

Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402

Informations de publication

Date de publication:
Jul 2020
Historique:
received: 03 06 2019
accepted: 02 01 2020
revised: 24 12 2019
pubmed: 3 2 2020
medline: 11 7 2020
entrez: 3 2 2020
Statut: ppublish

Résumé

Epithelial to mesenchymal transition (EMT) is a complex plastic and reversible cellular process that has critical roles in diverse physiological and pathological phenomena. EMT is involved in embryonic development, organogenesis and tissue repair, as well as in fibrosis, cancer metastasis and drug resistance. In recent years, the ability to edit the genome using the clustered regularly interspaced palindromic repeats (CRISPR) and associated protein (Cas) system has greatly contributed to identify or validate critical genes in pathway signaling. This review delineates the complex EMT networks and discusses recent studies that have used CRISPR/Cas technology to further advance our understanding of the EMT process.

Identifiants

pubmed: 32008085
doi: 10.1007/s00018-020-03449-3
pii: 10.1007/s00018-020-03449-3
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2701-2722

Auteurs

Reza Mohammadinejad (R)

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Alessio Biagioni (A)

Section of Experimental Pathology and Oncology, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence, Italy.

Ganesan Arunkumar (G)

Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Rebecca Shapiro (R)

Department of Molecular and Cellular Biology, University of Guelph, Guelph, ON, Canada.

Kun-Che Chang (KC)

Department of Ophthalmology, School of Medicine, Byers Eye Institute, Stanford University, Palo Alto, CA, 94303, USA.

Mohammed Sedeeq (M)

Division of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia.

Aftab Taiyab (A)

Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, L8S 4L8, Canada.

Mohammad Hashemabadi (M)

Department of Biology, Faculty of Sciences, Shahid Bahonar University, Kerman, Iran.
Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.

Abbas Pardakhty (A)

Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Ali Mandegary (A)

Physiology Research Center, Institute of Neuropharmacology and Department of Toxicology & Pharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Jean-Paul Thiery (JP)

Guangzhou Regenerative Medicine and Health, Guangdong Laboratory, Guangzhou, China.

Amir Reza Aref (AR)

Department of Medical Oncology, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. Amir_aref@hms.harvard.edu.

Iman Azimi (I)

Division of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, TAS, Australia. iman.azimi@utas.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH